Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have received a consensus rating of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $93.3333.

Several equities analysts have recently issued reports on PBH shares. Wall Street Zen lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Royal Bank Of Canada upgraded Prestige Consumer Healthcare to a “hold” rating in a research report on Thursday, May 8th. Finally, Canaccord Genuity Group decreased their target price on Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating for the company in a research report on Friday, August 8th.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several institutional investors have recently modified their holdings of the stock. Kayne Anderson Rudnick Investment Management LLC grew its position in shares of Prestige Consumer Healthcare by 45.3% during the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,580,819 shares of the company’s stock worth $135,903,000 after buying an additional 493,199 shares during the period. Geode Capital Management LLC grew its position in shares of Prestige Consumer Healthcare by 0.7% during the 2nd quarter. Geode Capital Management LLC now owns 1,413,041 shares of the company’s stock worth $112,843,000 after buying an additional 9,455 shares during the period. Invesco Ltd. grew its position in shares of Prestige Consumer Healthcare by 24.7% during the 1st quarter. Invesco Ltd. now owns 1,321,800 shares of the company’s stock worth $113,635,000 after buying an additional 261,537 shares during the period. Congress Asset Management Co. grew its position in shares of Prestige Consumer Healthcare by 1.8% during the 2nd quarter. Congress Asset Management Co. now owns 1,009,595 shares of the company’s stock worth $80,616,000 after buying an additional 18,015 shares during the period. Finally, Westwood Holdings Group Inc. grew its position in shares of Prestige Consumer Healthcare by 2.4% in the 2nd quarter. Westwood Holdings Group Inc. now owns 881,908 shares of the company’s stock valued at $70,420,000 after purchasing an additional 20,626 shares during the period. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Price Performance

Shares of PBH stock opened at $66.7550 on Friday. The stock has a 50-day moving average price of $75.29 and a 200 day moving average price of $81.18. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55. The firm has a market cap of $3.29 billion, a price-to-earnings ratio of 15.67, a PEG ratio of 2.07 and a beta of 0.43. Prestige Consumer Healthcare has a 12 month low of $62.95 and a 12 month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.95 EPS for the quarter, missing analysts’ consensus estimates of $1.01 by ($0.06). The firm had revenue of $249.53 million during the quarter, compared to analyst estimates of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.Prestige Consumer Healthcare’s revenue for the quarter was down 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Research analysts expect that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.